GHP November 2016

ghp November 2016 | 25 industry and will launch a similar program internationally. The program area employs a unique and robust stakeholder engagement model to enable collaboration between government, industry and academia and the co-development of solutions to complex health care challenges. The structure of the IHE, its unique positioning as a ‘neutral broker’ within the health care ecosystem, broad competencies, mature engagement and communication vehicles, and network leadership enable the program area to support industry to maximise economic and clinical opportunities in the life sciences sector. Commissioning The Institute of Health Economics can be contracted by both public and private sector organizations in any area of core service. The IHE has deep competencies in health economics and technology assessment to produce, synthesise or generate evidence and decision supports, and offers neutrality and unique capabilities to enable collaboration between sectors and the development of consensus and shared purpose in healthcare as well as in social services, educational and human services, and in the criminal justice system. Please contact us to discuss how we can be engaged in support of evidence-informed healthcare and other sector policy and practice. Egon Jonsson Egon Jonsson is the executive director and CEO of the Institute of Health Economics (IHE) in Edmonton, Canada, and Adj Professor of health economics at the University of Alberta and the University of Calgary. He was trained at the Stockholm School of Economics, Sweden, (PhD) and as a research associate at Harvard School of Public Health, US. Egon Jonsson is an elected member of the US National Academy of Medicine. Until recently he was co-editor, with Prof Stanley Reiser, Uof Texas, of the International Journal of Technology Assessment in Health Care, Cambridge University Press. For many years, he was the CEO of the Swedish Agency on Health Technology Assessment (SBU), and professor of Health Economics at the Department of Medicine, the Karolinska Institute, Stockholm, Sweden. He later worked for WHO as a leader in establishing The Health Evidence Network (HEN).and a health policy advisor at the Ministry of Health in Vietnam. In 2005 he moved to Canada to take on the position he still holds at the IHE in Edmonton, Canada. His main field of research and policy development is in health technology assessment including economic, social and ethical implications of both new and established medicines, devices, procedures, and programs.